Preliminary Program
(May 18, 2022)

VACCINE TECHNOLOGY VIII

June 12 - 17, 2022

Sitges, Spain
Melia Sitges Hotel

Conference Co-Chairs

Francesc Godia
Universitat Autònoma de Barcelona, Spain

Linda Hwee-Lin Lua
University of Queensland, Australia

Charles Lutsch
Sanofi, France

Tarit Mukhopadhyay
Merck Research Laboratories, USA

Engineering Conferences International
32 Broadway, Suite 314 - New York, NY 10004, USA
www.engconfintl.org – info@engconfintl.org

Sunday, June 12, 2022

15:00 – 17:30	Conference check-in
17:30 – 18:00	Opening remarks
18:00 – 19:00	**KEYNOTE** **A tale of two worlds from the ongoing pandemic – unprecedented successes and all too familiar failures** David Robinson, The Bill & Melinda Gates Foundation, USA
19:00 – 21:30	Reception and Dinner

Monday, June 13, 2022

07:00 – 08:30	Breakfast Buffet
	Session 1: Technological and clinical advances in vaccinology Chairs: Florian Krammer, Icahn School of Medicine at Mount Sinai, USA Julià Blanco, IRSI Caixa, Spain
08:30 – 09:00	**Lead Speaker** **Advances in therapeutic HIV vaccine development** Christian Brander, IRSI Caixa, Spain
09:00 – 09:20	**A single injection of a trimeric Ebola GP1/2 protein variant produced at 0.5 g/L in Chinese hamster ovary cells generates sterilizing protection in a novel mouse model for Ebola virus infection** Paco Pino, ExcellGene SA, Switzerland
09:20 – 09:40	**Microarray patch delivery of un-adjuvanted influenza vaccine induces potent and broad-spectrum immune responses in a phase I clinical trial** Alexandra C. I. Depelsenaire, Vaxxas Pty Ltd, Australia
09:40 – 10:00	**Development of a thermostable, multivalent filovirus vaccine based on recombinant subunit proteins** Axel T. Lehrer, University of Hawaii, USA
10:00 – 10:30	Coffee Break
	Session 2: Technological and clinical advances in vaccinology Chairs: Sandy Douglas, University of Oxford, United Kingdom Barry Buckland, BioLogicB LLC, USA
10:30 – 11:00	**The inactivated NDV-HXP-S COVID-19 vaccine induces a significantly higher ratio of neutralizing to non-neutralizing antibodies in humans as compared to mRNA vaccines** Juan Manuel Carreño, Icahn School of Medicine at Mount Sinai, USA
11:00 – 11:20	**Targeting endogenous retroviruses using a novel adenoviral vaccine technology** Anne-Marie Andersson, InProTher ApS, Denmark
11:20 – 11:40	**Killed but metabolically active Pseudomonas aeruginosa-based vaccine induces protective humoral- and cell-mediated immunity against Pseudomonas aeruginosa pulmonary infection** Sarah Thiroux, UGA, CNRS, CHU, France
11:40 – 12:00	**Superior SARS-CoV-2 RBD antigen designs for highly specific, quantitative serotests** Miriam Klausberger, University of Natural Resources and Life Sciences, Austria
12:00 – 13:30	Lunch
13:30 – 14:30	**KEYNOTE ON COVID-19 VACCINE** **Learnings from the development of Covid-19 vaccines** Kathrin Jansen, Pfizer, USA

Monday, June 13, 2022 (continued)

14:30 – 16:00	**Workshop: Innovation in Global Health** Workshop chairs: David Robinson, The Bill & Melinda Gates Foundation, USA Tarit Mukhopadhyay, Merck Research Laboratories, USA
16:00 – 17:00	Coffee Break / Networking
18:30 – 20:00	Dinner
20:00 – 22:00	**Poster session 1 (Odd numbers)** Poster Chairs: Laura Cervera, UAB, Spain Antonio Roldao, IBET, Portugal

Tuesday, June 14, 2022

07:00 – 08:30	Breakfast Buffet
	Session 3: Next generation platforms Chairs: Amine Kamen, McGill University, Canada Fu Tong-Ming, IGM Biosciences, Inc., USA
08:30 – 09:00	**Lead Speaker** **Discovery & Development of Therapeutic Interfering Particles (TIPs): single-administration SARS-CoV-2 and HIV antivirals with high barriers to the evolution of resistance** Leor Weinberg, University of California, San Francisco, USA
09:00 – 09:15	**Towards a platform process for the manufacture of glycoconjugate vaccines for pneumococcal disease** Neha Patel, University College London, United Kingdom
09:15 – 09:30	**Enabling technologies for manufacturing thermostable and cost-effective vaccines** Justin Stanbro, Merck & Co., Inc., USA
09:30 – 09:45	**Antibiotic-free expression platform development for Phaeodactylum tricornutum producing high value recombinant proteins** Greta Csalane Besenyei, University College London, United Kingdom
09:45 – 10:00	**Genomics of Vero cells: Understanding this cell line and its virus-host interactions for improved vaccine production** Marie-Angelique Sene, McGill University, Canada
10:00 – 10:30	Coffee Break
10 30 – 12:00	**Workshop** **Crafting a Career in Bioscience** Workshop Chairs: Linda Lua, University of Queensland, Australia Manon Cox, Next Wave Bio, USA
12:00 – 13:30	Lunch
	Session 4 and 5: Bioprocessing advances in vaccine manufacturing Chairs: Martina Micheletti, University College London, United Kingdom Paula Alves, IBET, Portugal Joseph Joyce, Merck & Co., Inc., USA
13:30 – 14:00	**Lead Speaker** **From genome to structure and beyond** Mariagrazia Pizza, GSK Vaccines, Italy
14:00 – 14:20	**Production of influenza A virus defective interfering particles in a high cell density perfusion cultivation with continuous virus harvesting** Marc D. Hein, Max Planck Institute and Otto von Guericke University, Germany
14:20 – 14:40	**Development of an automated microscale platform for conjugate vaccine production in *E. coli*** Jasmin J. Samaras, University College London, United Kingdom

Tuesday, June 14, 2022 (continued)

14:40 – 15:00	**Development of a purification process for HIV-1 VLPs based on four steps, from supernatant to lyophilization** Elianet Lorenzo Romero, Universitat Autonoma de Barcelona, Spain
15:00 – 15:20	**AMBR®250 HT System: A key process development tool for new live virus and microbial vaccine candidates** Jessica Olson, Merck & Co, Inc., USA
15:20 – 15:40	**Enhancement of PCV viral antigen production: combined effect of feed based on metabolic requirements and mild hypothermia** Ziomara Gerdtzen, University of Chile, Chile
15:40 – 16:00	**Accelerating and intensifying manufacturing to enable large-scale supply of a new adenovirus-vectored vaccine within 100 days** Sandy Douglas, University of Oxford, United Kingdom
16:00	Sitges activities Dinner on your own

Wednesday, June 15, 2022

07:00 – 08:30	Breakfast
	Session 6: Vaccine analytics I Chairs: Paula Lei, NIH/VRC, USA Cristiana Kampa, GlaxoSmithKline, United Kingdom
08:30 – 09:00	**Lead Speaker** **Driving change in dtap batch release testing** Isabelle Bekeredjian-Ding, Paul-Ehrlich-Institute, Germany
09:00 – 09:20	**The implication of glycans on the ACE2: SARS-CoV-2 spike interaction** Manuel Reithofer, University of Natural Resources and Life Sciences, Austria
09:20 – 09:40	**Generation of an international standard serum to measure influenza virus hemagglutinin stalk-reactive antibodies** Juan Manuel Carreno Quiroz, Icahn School of Medicine at Mount Sinai, USA
09:40 – 10:00	**New insights in formaldehyde-induced detoxification of the tetanus toxin: Chemical modification stoichiometry and characterization of intra- and inter-molecular cross-links** Thierry Eynard, Sanofi, France
10:00 – 10:30	Coffee Break
	Session 7: Vaccine analytics II Chairs: Laura Palomares, UNAM, Mexico Patrice Riou, Sanofi, France
10:30 – 10:45	**Development of analytical characterization tools for process monitoring of adenovirus-based vaccines (ChAdOx and Ad5)** Shaleem I. Jacob, University College London, United Kingdom
10:45 – 11:00	**Novel application of flow virometry to monitor live virus vaccines** Geoffrey Ricci, Merck & Co, Inc., USA
11:00 – 11:15	**On-Line influenza virus quantification for viral production processes thanks to affinity-based surface plasmon resonance biosensor** Emma Petiot, ICBMS-Gembas Laboratory, France
11:15 – 11:30	**All doses are not the same: Potential role of vaccine quality in vaccine adverse reactions** Bruce Yu, University of Maryland, USA
11:30 – 12:00	Panel Discussion
12:00 – 13:30	Lunch
13:30 – 14:30	**KEYNOTE** **Development of the Oxford AstaZeneca Covid Vaccine** Sarah Gilbert, University of Oxford, UK

Wednesday, June 15, 2022 (continued)

14:30 – 16:00 **Workshop: Intensified Vaccine Manufacturing**
Workshop Chairs: Udo Reichl, Max-Planck-Institut Magdeburg, Germany
Charles Lutsch, Sanofi, France

Intensified manufacturing of engineered exosomes and their potential in advanced vaccine design
Konstantin Konstantinov, Codiak BioSciences, Inc., USA

An aseptic platform process for recombinant measles viruses
Viktoria Mayer, BOKU, Vienna, Austria

How can process intensification solve bottlenecks in vaccine manufacturing?
Amélie Boulais, Sartorius Stedim FMT S.A.S., France

Process intensification considerations for LMIC
Philippe Alexandre Gilbert, Bill & Melinda Gates Foundation, USA

How does process intensification impact distributed manufacturing and access?
Tania Pereira, Univercells Technologies, Belgium

Discussion

16:00 – 17:00 Coffee Break

Session 8: One health
Chairs: Diego Fontana, Universidad Nacional Del Litoral, Argentina
Jean-Christophe Audonnet, Former Animal Health - Vaccine Industry leader, France

17:00 – 17:30 **Developing a 'One Health' Nipah virus vaccine to protect animal and public health**
Simon P. Graham, The Pirbright Institute, UK

17:30 – 17:50 **Design of mimotopes of a conserved epitope in dengue and Zika viruses for the obtention of broadly neutralizing antibodies**
Esmeralda Cuevas-Juárez, Instituto de Biotecnología, Mexico

17:50 – 18:10 **Sustained delivery of therapeutic nanobody cargo at the mucosal surfaces by engineered Limosilactobacillus reuteri**
Sambuddha Ghosh, Abel BioSolutions, Pune, India

18:10 – 18:30 **Adenovirus-based vaccine platform for mucosal or parenteral immunization of chickens**
Omar Famos, McGill University, Canada

18:30 – 20:00 Dinner

20:00 – 22:00 **Poster session 2 (Even numbers)**
Poster Chairs: Laura Cervera, UAB, Spain
Antonio Roldao, IBET, Portugal

Thursday, June 16, 2022

07:00 – 08:30	Breakfast
	Session 9: Formulation and delivery Chairs: QinJian Zhao, Xiamen University, China Lakshmi Khandke, PATH Center for Vaccine Innovation and Access, USA
08:30 – 09:00	**Lead Speaker** **Challenges and opportunities to formulate and stabilize vaccine candidates targeted for use in LMICs** David Volkin, The University of Kansas, USA
09:00 – 09:20	**Development of an oral protein subunit COVID-19 vaccine to induce mucosal and systemic immune response** Elodie Burlet, VaxForm, LLC, USA
09:20 – 09:40	**TBA**
09:40 – 10:00	**Development of sulfated lactosyl archaeol (SLA) archaeosomes as a vaccine adjuvant** Michael McCluskie, National Research Council Canada, Canada
10:00 – 10:30	Coffee Break
10:40 – 12:00	**Workshop: Next Gen Sequencing** Workshop chairs: Jean-Pol Cassart, GSK, United Kingdom Marc Eloit, Institut Pasteur, France
12:00 – 13:30	Lunch
	Session 10: Capacity building and intervention plan Chairs: Martin Elsenhawer, WHO, Switzerland Matthew Downham, CEPI, United Kingdom
13:30 – 14:00	**Lead Speaker** **Disease X development and 100 days initiative** Nicolas Havelange, CEPI, United Kingdom
14:00 – 14:24	**Developing an end to end manufacturing platform for self-amplifying messenger RNA vaccines** Kunal Aggarwal, GSK, USA
14:24 – 14:48	**A rapid response vaccine manufacturing platform as a countermeasure to epidemic threats** Tania Pereira Chilima, Univercells Technologies S.A., Belgium
14:48 – 15:12	**Advancing vaccine development and manufacture in Africa** Patrick Tippoo, African Vaccine Manufacturing Initiative, South Africa
15:12 – 15:36	**Test tubes and turnaround times: An accelerated biosafety testing approach for new vaccines against emerging pathogens** Sarah Sheridan, Merck, United Kingdom

Thursday, June 16, 2022 (continued)

15:36 – 16:00	**Production of high-quality SARS-CoV-2 antigens for vaccine development and serological assays implementation** Bárbara Fernandes, IBET, Portugal
16:00 – 16:30	Coffee Break
16:30 – 17:30	Poster short talks
17:30 – 18:30	**KEYNOTE** **Shifting the paradigm from global to national: innovative approaches for sustainable production of priority vaccines** Birgitte Giersing, WHO
18:30 – 19:00	Closing Conference Chairs
19:00 – 22:00	Banquet

Friday, June 17, 2022

07:00 – 10:00	Breakfast, Checkout and Departures